You can buy or sell Syros and other stocks, options, ETFs, and crypto commission-free!
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Read More The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Simply Wall StMar 13
What Should We Expect From Syros Pharmaceuticals, Inc.’s (NASDAQ:SYRS) Earnings In The Years Ahead?
Syros Pharmaceuticals, Inc.’s (NASDAQ:SYRS) most recent earnings announcement in December 2018 showed that losses became smaller relative to the prior year’s level as a result of recent tailwinds Investors may find it useful to understand how market analysts view Syros Pharmaceuticals’s earnings growth outlook over the next couple of years and whether the future looks brighter. I will be looking at earnings excluding extraordinary items to exclude one-off activities to get a better understanding of the unde...
The Motley FoolMar 7
Syros Pharmaceuticals, Inc. (SYRS) Q4 2018 Earnings Conference Call Transcript
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2018 Earnings Conference Call , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Quarter Four 2018 Syros Pharmaceuticals Incorporated Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct the question-and-answer session and instructions will follow at that time. (Operator Instructions) I would n...
Stock Price, News, & Analysis for Syros Pharmaceuticals
News stories about SYRS stock have been trending somewhat positive on Monday, according to InfoTrie. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a news impact score of 1.1 on InfoTrie's scale. They also gave news articles about the company a ne...
-$0.49 per share
-$0.54 per share